ORIGINAL ARTICLE

Open Access

Check for updates

Optimal debulking surgery in ovarian cancer patients: MRI may predict the necessity of rectosigmoid resection

Xiaofang Zhao¹, Ping Yang¹, Liu Liu¹, Yi Li¹, Yang Huang¹, Huali Tang¹, Yin Zhou^{1*} and Yun Mao^{1*}

Abstract

Objectives To determine whether MRI can predict the necessity of rectosigmoid resection (RR) for optimal debulking surgery (ODS) in ovarian cancer (OC) patients and to compare the predictive accuracy of pre- and post-neoadjuvant chemotherapy (NACT) MRI.

Methods The MRI of 82 OC were retrospectively analyzed, including six bowel signs (length, transverse axis, thickness, circumference, muscularis involvement, and submucosal edema) and four para-intestinal signs (vaginal, parametrial, ureteral, and sacro-recto-genital septum involvement). The parameters reflecting the degree of muscularis involvement were measured. Patients were divided into non-RR and RR groups based on the operation and postoperative outcomes. The independent predictors of the need for RR were identified by multivariate logistic regression analysis.

Results Imaging for 82 patients was evaluated (67 without and 15 with NACT). Submucosal edema and muscularis involvement (OR 13.33 and 8.40, respectively) were independent predictors of the need for RR, with sensitivities of 83.3% and 94.4% and specificities of 93.9% and 81.6%, respectively. Among the parameters reflecting the degree of muscularis involvement, circumference \geq 3/12 had the highest prediction accuracy, increasing the specificity from 81.6% for muscularis involvement only to 98.0%, with only a slight decrease in sensitivity (from 94.4% to 88.9%). The predictive sensitivities of pre-NACT and post-NACT MRI were 100.0% and 12.5%, respectively, and the specificities were 85.7% and 100.0%, respectively.

Conclusions MRI analysis of rectosigmoid muscularis involvement and its circumference can help predict the necessity of RR in OC patients, and pre-NACT MRI may be more suitable for evaluation.

Critical relevance statement We analyzed preoperative pelvic MRI in OC patients. Our findings suggest that MRI has predictive potential for identifying patients who require RR to achieve ODS.

Key Points

- The need for RR must be determined to optimize treatment for OC patients.
- Muscularis involvement circumference $\ge 3/12$ could help predict RR.
- Pre-NACT MRI may be superior to post-NACT MRI in predicting RR.

Xiaofang Zhao and Ping Yang contributed equally to this work.

*Correspondence: Yin Zhou zyin1988@126.com Yun Mao maoyun1979@163.com ¹Department of Radiology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China



© The Author(s) 2024. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.



Introduction

Debulking surgery and platinum-based chemotherapy are the main treatments for ovarian cancer (OC) patients [1]. The residual disease (RD) diameter after surgery is an independent prognostic factor in OC patients. Previous studies have confirmed that patients with optimal debulking surgery (ODS) (i.e., $RD \le 1 cm$) have better progression-free survival and overall survival than patients without ODS. Therefore, the surgical goal for OC is to achieve ODS [2-7]. Invasion of the rectosigmoid colon is the leading cause of RD and constitutes an important factor affecting whether ODS is feasible [8–12]. Rectosigmoid resection (RR) is a radical treatment. In patients with severe rectosigmoid involvement, failure to perform RR may result in recurrence in situ or bowel injury due to forced excision [13, 14]. However, when rectosigmoid involvement is mild, RR is an unnecessary surgical trauma [15]. A colorectal surgeon or a gynecologic oncologist trained in enterectomy is needed to complete RR [16]. Therefore, it is essential to accurately determine whether RR is necessary for OC patients.

However, current methods used to evaluate the rectosigmoid colon in OC patients have limitations. Colonoscopy can observe only the lumen of the bowel; because rectosigmoid invasion progresses from the serosa to the mucosa, the sensitivity of this technique is low [17-19]. Conventional contrast-enhanced CT and CT enterography (CTE) have low sensitivity due to the low soft tissue resolution and rectosigmoid colon collapse that easily obscures the lesions [20-22]. Transvaginal sonography is limited by its inability to observe lesions in the upper rectum and sigmoid [23]. Although diagnostic laparoscopy and exploratory laparotomy are currently the most commonly used evaluation methods, patients may suffer unnecessary trauma [24, 25]. MRI, due to its noninvasive nature and high soft tissue resolution, has become an important preoperative imaging examination for OC patients [26]. Rizzo et al [27] diagnosed rectosigmoid involvement in OC based on axial T2WI and diffusionweighted imaging (DWI), and the results showed high sensitivity (94.2%) and low specificity (40.0%). Indeed, the assessment of rectosigmoid involvement requires a combination of multiplanar and multiparametric, morphological and functional, and unenhanced and contrastenhanced sequences. MRI has been widely used in the preoperative evaluation of rectal cancer, but whether it is suitable for the preoperative prediction of RR in OC patients requires further study [28]. Additionally, it is not yet known which is the more appropriate reference image for RR decision-making in patients undergoing neoadjuvant chemotherapy (NACT), pre-NACT MRI, or post-NACT MRI.

This study aimed to determine whether preoperative MRI could accurately predict OC patients who require RR to achieve ODS and to compare the predictive accuracy of pre-NACT MRI and post-NACT MRI in patients receiving NACT.

Methods

Study population

The inclusion criteria were patients who underwent debulking surgery and were pathologically confirmed OC (including tubal and primary peritoneal cancers, collectively referred to as OC in our study) at our institution from January 2012 to May 2022. Exclusion criteria: (1) patients without preoperative pelvic MRI were excluded; (2) due to the need to compare the prediction accuracy of pre- and post-NACT MRI, patients who received NACT but lacked pre-NACT baseline MRI and/or post-NACT MRI were excluded; (3) since fat-suppressed T2WI cannot clearly display the structure of the intestinal wall, patients without axial and/or sagittal non-fat-suppressed T2WI were excluded; (4) to avoid affecting the evaluation results due to changes in condition, patients with more than 30 days between the last preoperative MRI examination and surgery were excluded; (5) patients with poor image quality or in whom the cross-section of the affected bowel cannot be visualized were excluded; (6) patients with no lesions in the rectosigmoid colon and no related intestinal operations during surgery were excluded; (7) patients with the Federation International of Gynecology and Obstetrics (FIGO) stage I were excluded; and (8) patients without postoperative follow-up images for at least 1 year were excluded.

MRI technique

MR examinations were performed using one 1.5-T MRI scanner (Singa HD Excite, GE Healthcare, USA) and three 3.0-T MRI scanners (Singa HD Excite, GE Healthcare, USA; Magnetom Skyra, Siemens Healthineers, Germany; Ingenia, Philips Healthcare, Best, The Netherlands) with pelvic phased-array coils. All MRI protocols included at least axial or sagittal T2-weighted non-fat-suppressed images, axial T1-weighted fat-suppressed or non-fat-suppressed images, axial DWI (b values of 0, 800, and 1000 s/mm²), and axial dynamic contrast-enhanced (DCE) T1WI. The contrast agent was Magnevist (Ga-DTPA, Bayer Pharma AG, Germany) with an injection dose of 0.2 mL/kg and an injection flow rate of 2–3 mL/s. Supplemental Table 1 provides the scanning parameters.

Image analysis

MRI analysis of all OC patients was performed independently on a picture archiving and communication system (Carestream, GCRIS, Shanghai, China) workstation by two radiologists with more than 10 years of experience in abdominal MRI diagnosis (radiologist Y.Z.) and 3 years of experience (radiologist X.F.Z.), who were blinded to previous imaging reports, surgical information, and histopathological information.

MRI analysis included six bowel signs (length, transverse axis, thickness, circumference of rectosigmoid involvement, muscularis involvement, and submucosal edema) (Fig. 1) and four para-intestinal signs (vaginal, parametrial, ureteral, and sacro-recto-genital septum involvement) (Fig. 2). Axial and sagittal non-fat-suppressed T2WI were the main sequences. The evaluation criteria and procedures were as follows: (1) the lesions were identified on T2WI, DWI, and DCE T1WI. Rectosigmoid involvement was defined as loss of the fat plane between the bowel wall and the lesions, with at least a "minimal" thickening of the serosal layer of the bowel wall and continuous with the lesions [29]. Then, the length, transverse axis, thickness, and circumference of rectosigmoid involvement were measured. The length was measured along the involved bowel wall on sagittal T2WI. Thickness and transverse axis were measured at the deepest and widest point of bowel involvement on axial or sagittal T2WI, respectively. The circumference was scored by dividing the cross-section of the bowel into 12 equal parts. When the bowel involvement was multifocal, the length was the sum of all segments, and the transverse axis, thickness, and circumference were the maximum values. (2) Determined whether muscularis involvement was present. Muscularis involvement was defined as the loss of the fat plane between the bowel wall and the lesions, accompanied by the loss of the normal T2-hypointensity of the muscularis (with or without a "fanshaped" configuration) [29]. Then, parameters reflecting the degree of muscularis involvement, i.e., the length, transverse axis, thickness, and circumference of muscularis involvement, were measured. (3) Determined whether submucosal edema was present. Submucosal edema was defined as high intensity at the luminal side of the involved bowel wall on T2WI. (4) The evaluation criteria for the four para-intestinal signs were as follows: vaginal involvement manifesting as tumoral nodules extending to the normal T2-hypointense vaginal wall. Parametrial involvement was defined as tumoral nodules extending to the parametrium. Ureteral involvement, either unilateral or bilateral, was defined as loss of the fat plane between the lesion and ureter with ureteral dilatation. Sacro-recto-genital septum involvement, either unilateral or bilateral, was defined as nodular or irregular thickening [30]. (5) For patients undergoing NACT, pre-NACT baseline MRI and the



Fig. 1 Illustration of bowel MRI signs. a Sagittal T2WI shows "minimal" thickening of the serosal layer of the rectosigmoid wall and continuous with the lesions and shows measurements of the length of rectosigmoid involvement (white line). b Sagittal T2WI shows the loss of the normal T2-hypointensity of the muscularis in a "fan-shaped" configuration, along with submucosal edema (single arrow), and shows the measurements of length (white line) and thickness (double arrow) of muscularis involvement. c Axial T2WI shows the measurement of the transverse axis of muscularis involvement (white line). d Axial T2WI shows the rectosigmoid circumference divided into 12 equal parts to evaluate the circumference of muscularis involvement and shows muscularis involvement along 4/12 of the circumference

last preoperative MRI were evaluated in the same way as described above.

Surgical data and grouping criteria

All operations were performed by a gynecologic oncologist experienced in debulking surgery, or a colorectal surgeon experienced in enterectomy if enterectomy was determined. The actual surgical method may not be the best surgical method for achieving ODS. Thus, the rectosigmoid conditions during the operation (including bowel wall injury, lumen stenosis, and RD) and postoperative outcomes (including pathological results and recurrence in situ at least 1 year after surgery) were used as supplementary bases for the classification of actual surgical results. All patients' clinical data were obtained from the electronic medical record system. RD in this study specifically referred to postoperative RD on the rectosigmoid colon, excluding RD elsewhere. The actual surgical results were divided into eight types, designated type 1–type 8. Then, according to these eight actual surgical results, the patients were divided into a non-RR group and an RR group (Table 1). Among these groups, the actual type 1–type 2 bowel surgery was non-RR, and the postoperative outcomes also confirmed that the ideal operation was non-RR. The actual type 3 bowel surgery was RR, but the postoperative outcomes indicated that the ideal operation was non-RR. The actual type 4–7 bowel surgery was non-RR, but the postoperative outcomes indicated that the ideal operation was RR. The actual type 8 bowel surgery was RR, and the postoperative outcomes also confirmed that the ideal operation was RR.

Statistical analysis

Statistical analysis was performed with SPSS software (version 25.0; SPSS Inc., Chicago, IL, USA). Categorical variables were expressed as counts and percentages, and



Fig. 2 Illustration of para-intestinal MRI signs. **a** Sagittal T2WI shows tumoral nodules extending to the normal T2-hypointense vaginal wall. **b** Axial T2WI shows tumoral nodules extending to the right parametrium. **c** Axial T2WI shows the loss of the fat plane between the lesion and the left ureter with ureteral dilatation. **d** Axial T2WI shows tumoral nodules extending to the left sacro-recto-genital septum with nodular thickening of the left sacro-recto-genital septum

Tab	le '	1 (Gro	uping	crite	eria	for	OC	patients
-----	------	-----	-----	-------	-------	------	-----	----	----------

Grouping	Actual surgical results
Non-RR group	Type 1. non-RR + no bowel wall injury + RD \leq 1 cm + no recurrence in situ at least 1 year after surgery.
	Type 2. non-RR + no lumen stenosis after the injured bowel wall was repaired + RD \leq 1 cm + no recurrence in situ at least 1 year after
	surgery.
	Type 3. RR + pathological results showed no rectosigmoid involvement.
RR group	Type 4. non-RR + no bowel wall injury + RD \leq 1 cm + recurrence in situ at least 1 year after surgery.
	Type 5. non-RR + RD > 1 cm + whether the bowel wall is injured or not.
	Type 6. non-RR + no lumen stenosis after the injured bowel wall was repaired + $RD \le 1 \text{ cm} + \text{recurrence}$ in situ at least 1 year after
	surgery.
	Type 7. non-RR + lumen stenosis after the injured bowel wall was repaired + no matter if RD is ≤ 1 cm or > 1 cm.
	Type 8. RR + pathological results showed rectosigmoid involvement.

RR rectosigmoid resection, RD residual disease

comparisons between groups were performed using the chi-square test or Fisher exact probability test. Continuous variables were expressed as mean \pm standard deviation or median and interquartile range, and comparisons between groups were performed using Student's *t*-test or the non-parametric Mann–Whitney *U*-test. The interrater reliability was assessed by calculating intraclass correlation coefficients (ICCs) or



Fig. 3 The flow diagram of the patient selection process. NACT, neoadjuvant chemotherapy; FIGO, International Federation of Gynecology and Obstetrics; RR, rectosigmoid resection

weighted kappa coefficients. ICCs of < 0.50, 0.50-0.75,0.76-0.90, and 0.91-1.00 indicate poor, moderate, good, and excellent reliability, respectively [31]. Kappa values of 0.00-0.20, 0.21-0.40, 0.41-0.60, 0.61-0.80, and 0.81-1.00 indicate slight, fair, moderate, substantial, and almost perfect reliability, respectively [32]. Univariate analysis was performed for all MRI signs with ICC \geq 0.76 or kappa \geq 0.81. The image analysis results of senior radiologists were used for subsequent statistical analysis. All the variables with significant differences based on the univariate analysis were calculated by multivariate binary logistic regression. For continuous variables, the Youden index was used to determine the cutoff point that yielded the maximum sensitivity and specificity for predicting the necessity of RR. Predictive ability was evaluated by calculating sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy. p < 0.05 was considered a significant difference.

Results

Grouping and basic characteristics

A total of 82 OC patients were ultimately eligible for our study cohort (mean age: 53.3 ± 8.8 years; range: 31-75 years), including 67 patients without NACT (49 in the non-RR group and 18 in the RR group) and 15 patients with NACT (seven in the non-RR group and eight in the RR group). In this study, FIGO stages II, III, and IV accounted for 24.4%, 54.9%, and 20.7% of cases, respectively. The distribution of histological types included 68 (82.9%) cases of serous carcinoma, two (2.4%) mucinous carcinoma, six (7.3%) clear cell carcinoma, four (4.9%) endometrioid adenocarcinoma, and two (2.4%) other types. The surgical outcomes revealed 50 (61.0%) cases of type 1, 5 (6.1%) type 2, 1 (1.2%) type 3, 6 (7.3%) type 4, 13 (15.9%) type 5, and 7 (8.5%) type 8, whereas 0 both type 6 and type 7. The flow diagram of the patient selection process is shown in Fig. 3.

Univariate and multivariate analyses of patients without NACT

The MRI analysis results of patients without NACT are shown in Table 2. All patients with submucosa edema had muscularis involvement. The interrater reliability of all MRI signs was good, excellent, or almost perfect (ICCs from 0.86 to 0.96 and kappa from 0.87 to 1.00).

In the univariate analysis, all six bowel signs were associated with the necessity of RR (p < 0.05), among which submucosal edema and muscularis involvement were strongly positively associated with the necessity of RR (OR 76.67 and 75.56, respectively). Among para-intestinal signs, only parametrial involvement and sacro-recto-genital septum involvement were associated with the necessity of RR (p < 0.05). Among the seven patients with parametrial involvement, five had muscularis involvement, and among the 13 patients with sacro-recto-genital septum involvement, nine had muscularis involvement. In the multivariate analysis, submucosal edema (OR 15.00, 95% CI [1.98–113.56], p = 0.009) and muscularis involvement (OR 13.33, 95% CI [1.04–170.63], p = 0.046) were independent predictors of the need for RR (Table 3). The sensitivity, specificity, PPV, NPV, and accuracy of submucosal edema and muscularis involvement in predicting the

MRI signs	Non-RR group, (<i>n</i> = 49)	RR group, (<i>n</i> = 18)	
Length	37.0 (21.0–67.0)	85.5 (34.1, 116.8)	
Transverse axis	12.0 (7.0, 16.2)	18.5 (13.5–26.3)	
Thickness	0.0 (0.0–0.0)	2.0 (2.0–6.0)	
Circumference	2.0 (1.0-3.0)	3.0 (3.0-4.0)	
Muscularis involvement	9 (18.4)	17 (94.4)	
Length	0.0 (0.0–0.0)	61.5 (35.0–76.3)	
Transverse axis	0.0 (0.0–0.0)	17.0 (12.8–22.3)	
Thickness	0.0 (0.0–0.0)	4.5 (3.0–7.0)	
Circumference	0.0 (0.0–0.0)	3.0 (3.0-4.0)	
Submucosal edema	3 (6.1)	15 (83.3)	
Vaginal	1 (2.0)	2 (11.1)	
Parametrial	2 (4.1)	5 (27.8)	
Ureteral	1 (2.0)	0 (0.0)	
Sacro-recto-genital septum	5 (10.2)	8 (44.4)	
involvement			

Categorical variables were expressed as counts and percentages, skewed distributed quantitative data are expressed as median and interquartile range *RR* rectosigmoid resection

necessity of RR were 83.3%, 93.9%, 83.3%, 93.9%, and 91.0% and 94.4%, 81.6%, 65.4%, 97.6%, and 85.1%, respectively.

Analysis results of the muscularis involvement subgroup without NACT

MRI signs reflecting the degree of muscularis involvement were added to the subgroup analysis of patients without NACT. The interrater reliability of all parameters reflecting the degree of muscularis involvement was good or excellent (ICCs from 0.87 to 0.96).

According to the Youden index, the following cutoff points for measures of muscularis involvement were determined to maximize the probability of ODS and minimize the probability of unnecessary RR: length \geq 35 mm, transverse axis \geq 11 mm, thickness \geq 4 mm, and circumference \geq 3/12. Among these variables, the circumference \geq 3/12 predicted the necessity of RR with the highest predictive ability (Table 4). Following the inclusion of circumference \geq 3/12 of muscularis involvement, the specificity of MRI in predicting the need for RR increased from 81.6% when considering only muscularis involvement to 98.0%. The sensitivity experienced a slight decrease from 94.4% to 88.9%.

Compare the predictive results of pre- and post-NACT MRI Using a criterion of muscularis involvement circumference $\geq 3/12$ to predict the necessity of RR, one false-positive case was identified in the pre-NACT MRI prediction results, while the remaining 14 cases were accurately predicted. In the post-NACT MRI prediction results, there were seven false-negative cases, with the remaining eight cases accurately predicted. The evaluation results of pre- and post-NACT MRI are shown in Table 5.

Table 3 Univariate and multivariate analyses of patients without NACT

	Univariate a	analysis	Multivariate analysis			
MRI signs	OR	95% CI	p value	OR	95% Cl	p value
Length	1.01	(1.00, 1.02)	0.030			
Transverse axis	1.19	(1.07, 1.33)	0.002			
Thickness	6.48	(2.21, 18.97)	0.001			
Circumference	2.67	(1.51, 4.72)	0.001			
Submucosal edema	76.67	(13.96, 420.98)	< 0.001	15.00	(1.98, 113.56)	0.009
Muscularis involvement	75.56	(8.87, 643.79)	< 0.001	13.33	(1.04, 170.63)	0.046
Vaginal	6.00	(0.51, 70.67)	0.355			
Parametrial	9.04	(1.58, 52.07)	0.018			
ureteral	< 0.001	-	1.000 ^a			
Sacro-recto-genital septum	7.04	(1.90, 26.13)	0.002			

OR odds ratio, 95% CI 95% confidence interval

^a Fisher exact probability test

MRI signs ^a	Sensitivity	specificity	PPV	NPV	Accuracy
Length ≥ 35 mm	82.4 (14/17)	66.7 (6/9)	82.4 (14/17)	66.7 (6/9)	76.9 (20/26)
Transverse axis ≥ 11 mm	94.1 (16/17)	66.7 (6/9)	84.2 (16/19)	85.7 (6/7)	84.6 (22/26)
Thickness ≥ 4 mm	70.6 (12/17)	88.9 (8/9)	92.3 (12/13)	61.5 (8/13)	76.9 (20/26)
Circumference ≥ 3/12	94.1 (16/17)	88.9 (8/9)	94.1 (16/17)	88.9 (8/9)	92.3 (24/26)

 Table 4
 Ability of the degree of muscularis involvement to predict the necessity of RR

The data in parentheses are the numbers (n/n) used to calculate the percentage

PPV positive predictive value, NPV negative predictive value

^a All MRI signs are parameters reflecting the degree of muscularis involvement

Table 5 The predictive results of pre- and post-NACT MRI for the necessity of RR

		RR group	Non-RR group	Sensitivity	Specificity	PPV	NPV	Accuracy
Pre-NACT MRI	RR group	8	1	100.0%	85.7%	88.9%	85.7%	93.3%
	Non-RR group	0	6					
Post-NACT MRI	RR group	1	0	12.5%	100.0%	100.0%	50.0%	53.3%
	Non-RR group	7	7					

NACT neoadjuvant chemotherapy, RR rectosigmoid resection, PPV positive predictive value, NPV negative predictive value

Discussion

A critical factor in whether an OC patient will achieve ODS is the management of rectosigmoid colon involvement [8–12]. However, a tool that can accurately and noninvasively predict the necessity of RR is still lacking. Our study indicated that preoperative MRI could help identify OC patients who require RR by assessing whether the muscularis of the rectosigmoid colon is involved and, if so, what proportion of the circumference is involved. Furthermore, pre-NACT MRI may provide greater predictive accuracy than post-NACT MRI.

MRI can reliably diagnose rectosigmoid muscularis involvement. This study builds upon the MRI signs of intestinal muscularis involvement identified by Busard et al [29]. This study indicated that muscularis involvement is an independent predictor of RR. Additionally, all patients with submucosal edema had muscularis involvement, and submucosal edema may correspond to nonspecific inflammation caused by deeper involvement of the intestinal wall [29], which manifests itself as T2WI high signal on MRI. Therefore, submucosal edema could serve as an indirect indicator of muscularis involvement, explaining why previous studies have utilized stratification of the intestinal wall at the lesion on CT as a sign of muscularis involvement [33, 34]. Thus, in cases where direct signs of intestinal wall muscularis disruption are unclear, the presence of submucosal edema may aid in diagnosing muscularis involvement and enhance diagnostic sensitivity.

Nevertheless, not all OC patients with muscularis involvement require RR to achieve ODS [14]. Our findings have shown that the extent, especially the circumference, of

muscularis involvement is crucial for surgical decisions, which is similar to the results of Rousset et al [35] on endometriosis-related bowel resection. The high predictive accuracy of the circumference of muscularis involvement in this study may be explained by the study of Abrao et al [36]. They found that 89.3% of patients may have mucosal and submucosal involvement when bowel wall involvement exceeds 40% of the circumference. If only tumor excision is performed at this time, it will easily lead to irreparable intestinal wall rupture, necessitating the use of RR. Of course, further pathological verification is required. However, the accuracy of the length of muscularis involvement in predicting RR in this study was relatively low. This may be because repairing the injured small bowel perpendicular to its longitudinal axis is necessary to reduce the risk of luminal stenosis [14, 37]. But the rectosigmoid colon has a larger lumen, making it less likely to develop stenosis even if the repair is not performed perpendicular to the longitudinal axis of the bowel. Regarding para-intestinal signs in this study, parametrial and sacro-recto-genital septum involvement were positively correlated with RR, but they were not independent predictors. The reason may be that most patients with these two MRI signs also had muscularis involvement, making these variables redundant. Therefore, preoperative MRI evaluation of OC patients should include the extent of rectosigmoid muscularis involvement, especially the circumference.

It is not clear whether pre-NACT or post-NACT MRI is a better source of reference images for making decisions regarding RR in OC patients with NACT. In this study, the predictive sensitivity of post-NACT MRI was low. This may be because the signal of inactive fibrosis after NACT may mask the remaining active tumor [38]. It was difficult for MRI to accurately distinguish the remaining active tumors from inactive fibrosis even when enhanced imaging and DWI were used in our study. Recent studies have noted that there may be chemotherapeutic-resistant tumor stem cells in these residual tissues, which are not sensitive to postoperative chemotherapy drugs, and thus easy to cause in situ recurrence [39-42]. Structural disorders of all layers of the bowel wall after NACT also increase the difficulty of MRI evaluation, which is also the reason why T staging via post-NACT MRI for rectal cancer is inaccurate [43]. In this study, there was also one false positive case in the pre-NACT MRI prediction results. Upon analyzing the clinical and imaging data, it was discovered that the patient had isolated metastases confirmed by biopsy in the neck and lung. Following NACT treatment, the lung lesion completely disappeared, and the neck lesion significantly shrank. Although these lesions were not surgically removed, there was no recurrence or enlargement observed during the follow-up period. This suggests that the patient may be sensitive to postoperative chemotherapy drugs, and longer follow-up is necessary to determine the presence of in situ recurrence. But in general, for OC patients receiving NACT, pre-NACT MRI may be more suitable for assessing the necessity of RR.

This retrospective study has several limitations. Firstly, due to its retrospective nature, poorly recorded clinical data in some patients may have impacted the results; therefore, future prospective studies are necessary for further validation of the findings. Secondly, since intestinal recurrence observed by imaging cannot be distinguished from overall tumor recurrence, 1-year follow-up imaging may not accurately reflect postoperative outcomes. Thirdly, the sample size was small; thus, collecting more cases or seeking multicenter cooperation in the future is essential to obtain a larger cohort for further investigation. Fourthly, only MRI analysis was conducted in this study, without comparing the findings with those of other imaging examinations. Future analyses could consider combining MRI with conventional enhanced CT and CTE to improve the accuracy and reliability of results. Finally, the absence of oblique axial T2WI perpendicular to the longitudinal axis of the bowel in this study was partially addressed by excluding patients who could not display a cross-section of the affected bowel.

In conclusion, the presence and circumference of rectosigmoid muscularis involvement on preoperative MRI can help identify OC patients who require RR to achieve ODS. In patients undergoing NACT, pre-NACT MRI may be more appropriate for evaluating the need for RR compared to post-NACT.

Abbreviations

CI	Confidence interval
DCE	Dynamic contrast-enhanced
DWI	Diffusion-weighted imaging
FIGO	Federation International of Gynecology and Obstetrics
ICCs	Intraclass correlation coefficients
NACT	Neoadjuvant chemotherapy
NPV	Negative predictive value
OC	Ovarian cancer
ODS	Optimal debulking surgery
OR	Odds ratio
PPV	Positive predictive value
RD	Residual disease
RR	Rectosigmoid resection
	CI DCE DWI FIGO ICCs NACT NPV OC ODS OR PPV RD RR

Supplementary information

The online version contains supplementary material available at https://doi.org/10.1186/s13244-024-01725-5.

ELECTRONIC SUPPLEMENTARY MATERIAL

Author contributions

Conception and design: X.Z., P.Y., Y.M., and Y.Z. Acquisition of data: X.Z. and P.Y. Analysis/interpretation of data: all authors. Writing manuscript: X.Z. and P.Y. Approval of final manuscript: Y.L. and H.T. All authors read and approved the final manuscript.

Funding

This study was funded by the Program for Youth Innovation in Future Medicine, Chongqing Medical University [grant no. W0096/0302022Y2021284].

Data availability

The datasets used for analyses during the current study are available from the corresponding authors upon reasonable request.

Declarations

Ethics approval and consent to participate

This study was approved by the institutional review board of our center (approval number K2023-294), and the requirement of patient consent was waived due to the retrospective design.

Consent for publication

All participants provided written informed consent.

Competing interests

The authors declare that they have no competing interests.

Received: 20 March 2024 Accepted: 23 May 2024 Published online: 18 June 2024

References

- Lee YJ, Chung YS, Lee JY et al (2018) Impact of increased utilization of neoadjuvant chemotherapy on survival in patients with advanced ovarian cancer: experience from a comprehensive cancer center. J Gynecol Oncol 29:e63. https://doi.org/10.3802/jgo.2018.29.e63
- Lheureux S, Braunstein M, Oza AM (2019) Epithelial ovarian cancer: Evolution of management in the era of precision medicine. CA Cancer J Clin 69:280–304. https://doi.org/10.3322/caac.21559
- du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J (2009) Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively

randomized phase 3 multicenter trials by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO). Cancer 115:1234–1244. https://doi.org/10.1002/cncr. 24149

- Manning-Geist BL, Hicks-Courant K, Gockley AA et al (2018) Moving beyond "complete surgical resection" and "optimal": Is low-volume residual disease another option for primary debulking surgery? Gynecol Oncol 150:233–238. https://doi.org/10.1016/j.ygyno.2018.06.015
- Greer A, Gockley A, Manning-Geist B et al (2021) Impact of residual disease at interval debulking surgery on platinum resistance and patterns of recurrence for advanced-stage ovarian cancer. Int J Gynecol Cancer 31:1341–1347. https://doi.org/10.1136/ijgc-2020-001505
- Manning-Geist BL, Hicks-Courant K, Gockley AA et al (2019) A novel classification of residual disease after interval debulking surgery for advanced-stage ovarian cancer to better distinguish oncologic outcome. Am J Obstet Gynecol 221:326 e321–326 e327. https://doi.org/10.1016/j. ajog.2019.05.006
- Derlatka P, Sienko J, Grabowska-Derlatka L et al (2016) Results of optimal debulking surgery with bowel resection in patients with advanced ovarian cancer. World J Surg Oncol 14:58. https://doi.org/10.1186/s12957-016-0800-1
- Jaeger W, Ackermann S, Kessler H, Katalinic A, Lang N (2001) The effect of bowel resection on survival in advanced epithelial ovarian cancer. Gynecol Oncol 83:286–291. https://doi.org/10.1006/gyno.2001.6375
- Hoffman MS, Griffin D, Tebes S et al (2005) Sites of bowel resected to achieve optimal ovarian cancer cytoreduction: implications regarding surgical management. Am J Obstet Gynecol 193:582–586. https://doi.org/ 10.1016/j.ajog.2005.03.046. discussion 586–588
- Sebastian A, Thomas A, Varghese G, Yadav B, Chandy R, Peedicayil A (2018) Outcome of bowel resection in women with advanced ovarian carcinoma. Indian J Surg Oncol 9:511–518. https://doi.org/10.1007/ s13193-018-0790-2
- Ye S, Wang Y, Chen L, Wu X, Yang H, Xiang L (2022) The surgical outcomes and perioperative complications of bowel resection as part of debulking surgery of advanced ovarian cancer patients. BMC Surg 22:81. https://doi.org/10.1186/s12893-022-01531-0
- 12. Kim JH, Han WH, Lee DE et al (2023) Anastomotic leakage after resection of the rectosigmoid colon in primary ovarian cancer. J Ovarian Res 16:85. https://doi.org/10.1186/s13048-023-01153-x
- Aletti GD, Podratz KC, Jones MB, Cliby WA (2006) Role of rectosigmoidectomy and stripping of pelvic peritoneum in outcomes of patients with advanced ovarian cancer. J Am Coll Surg 203:521–526. https://doi. org/10.1016/j.jamcollsurg.2006.06.027
- 14. Mendez LE (2001) latrogenic injuries in gynecologic cancer surgery. Surg Clin North Am 81:897–923. https://doi.org/10.1016/s0039-6109(05)70173-0
- Erkilinc S, Karatasli V, Demir B et al (2018) Rectosigmoidectomy and douglas peritonectomy in the management of serosal implants in advanced-stage ovarian cancer surgery: survival and surgical outcomes. Int J Gynecol Cancer 28:1699–1705. https://doi.org/10.1097/lgc. 000000000001368
- Huddart D, Rajkumar S, Kolomainen D, Mehra G, Nath R, Sayasneh A (2022) Gynae-oncology surgeons' preparedness to undertake colorectal procedures during cytoreductive surgery for ovarian cancer: a cross sectional survey. J Clin Med 11:6233. https://doi.org/10.3390/ jcm11216233
- Ravizza D, Fiori G, Trovato C, Maisonneuve P, Bocciolone L, Crosta C (2005) Is colonoscopy a suitable investigation in the preoperative staging of ovarian cancer patients? Dig Liver Dis 37:57–61. https://doi.org/10. 1016/j.dld.2004.07.016
- Raś R, Barnaś E, Magierło JS et al (2019) Preoperative colonoscopy in patients with a supposed primary ovarian cancer. Medicine (Baltimore) 98:e14929. https://doi.org/10.1097/md.000000000014929
- Liu G, Yan J, Long S et al (2021) Is Routine gastroscopy/colonoscopy reasonable in patients with suspected ovarian cancer: a retrospective study. Front Oncol 11:608999. https://doi.org/10.3389/fonc.2021.608999
- Glaser G, Torres M, Kim BH et al (2013) The use of CT findings to predict extent of tumor at primary surgery for ovarian cancer. Gynecol Oncol 130:280–283. https://doi.org/10.1016/j.ygyno.2013.05.007

- Zhang XM, Zhang XY, Liu YX, Li RN, Li YM, Linghu H (2022) Computed tomographic enterography (CTE) in evaluating bowel involvement in patients with ovarian cancer. Abdom Radiol (NY) 47:2023–2035. https://doi.org/10.1007/s00261-022-03497-2
- 22. Takeda T, Hayashi S, Kobayashi Y et al (2021) Evaluation of preoperative prediction of intestinal invasion in patients with ovarian cancer. Int J Gynaecol Obstet 153:398–404. https://doi.org/10.1002/ijgo.13492
- Berton F, Gola G, Wilson SR (2008) Perspective on the role of transrectal and transvaginal sonography of tumors of the rectum and anal canal. AJR Am J Roentgenol 190:1495–1504. https://doi.org/10.2214/AJR.07.3188
- 24. Tozzi R, Traill Z, Campanile RG et al (2019) Diagnostic flow-chart to identify bowel involvement in patients with stage IIIC-IV ovarian cancer: Can laparoscopy improve the accuracy of CT scan? Gynecol Oncol 155:207–212. https://doi.org/10.1016/j.ygyno.2019.08.025
- Tozzi R, Traill Z, Valenti G, Ferrari F, Gubbala K, Campanile RG (2021) A prospective study on the diagnostic pathway of patients with stage IIIC-IV ovarian cancer: exploratory laparoscopy (EXL) + CT scan VS. CT scan. Gynecol Oncol 161:188–193. https://doi.org/10.1016/j.ygyno.2021.01.013
- Sadowski EA, Rockall A, Thomassin-Naggara I et al (2023) Adnexal lesion imaging: past, present, and future. Radiology 307:e223281. https://doi. org/10.1148/radiol.223281
- Rizzo S, De Piano F, Buscarino V et al (2020) Pre-operative evaluation of epithelial ovarian cancer patients: Role of whole body diffusion weighted imaging MR and CT scans in the selection of patients suitable for primary debulking surgery. A single-centre study. Eur J Radiol 123:108786. https:// doi.org/10.1016/j.ejrad.2019.108786
- Horvat N, Carlos Tavares Rocha C, Clemente Oliveira B, Petkovska I, Gollub MJ (2019) MRI of rectal cancer: tumor staging, imaging techniques, and management. Radiographics 39:367–387. https://doi.org/10.1148/rg. 2019180114
- Busard MP, van der Houwen LE, Bleeker MC et al (2012) Deep infiltrating endometriosis of the bowel: MR imaging as a method to predict muscular invasion. Abdom Imaging 37:549–557. https://doi.org/10.1007/ s00261-011-9790-1
- Bazot M, Darai E, Hourani R et al (2004) Deep pelvic endometriosis: MR imaging for diagnosis and prediction of extension of disease. Radiology 232:379–389. https://doi.org/10.1148/radiol.2322030762
- Koo TK, Li MY (2016) A guideline of selecting and reporting intraclass correlation coefficients for reliability research. J Chiropr Med 15:155–163. https://doi.org/10.1016/j.jcm.2016.02.012
- Landis JR, Koch GG (1977) The measurement of observer agreement for categorical data. Biometrics 33:159–174
- Biscaldi E, Ferrero S, Leone Roberti Maggiore U, Remorgida V, Venturini PL, Rollandi GA (2014) Multidetector computerized tomography enema versus magnetic resonance enema in the diagnosis of rectosigmoid endometriosis. Eur J Radiol 83:261–267. https://doi.org/10.1016/j.ejrad. 2013.10.010
- Biscaldi E, Ferrero S, Fulcheri E, Ragni N, Remorgida V, Rollandi GA (2007) Multislice CT enteroclysis in the diagnosis of bowel endometriosis. Eur Radiol 17:211–219. https://doi.org/10.1007/s00330-006-0364-5
- Rousset P, Buisson G, Lega JC et al (2021) Rectal endometriosis: predictive MRI signs for segmental bowel resection. Eur Radiol 31:884–894. https:// doi.org/10.1007/s00330-020-07170-4
- 36. Abrao MS, Podgaec S, Dias JA, Averbach M, Silva LFF, de Carvalho FM (2008) Endometriosis lesions that compromise the rectum deeper than the inner muscularis layer have more than 40% of the circumference of the rectum affected by the disease. J Minim Invas Gyn 15:280–285. https://doi.org/10.1016/j.jmig.2008.01.006
- Kim MS, Noh JJ, Lee YY (2021) En bloc pelvic resection of ovarian cancer with rectosigmoid colectomy: a literature review. Gland Surg 10:1195–1206. https://doi.org/10.21037/gs-19-540
- Patel UB, Blomqvist LK, Taylor F et al (2012) MRI after treatment of locally advanced rectal cancer: how to report tumor response-the MERCURY experience. AJR Am J Roentgenol 199:W486–W495. https://doi.org/10.2214/Ajr.11.8210
- Lim MC, Song YJ, Seo SS, Yoo CW, Kang S, Park SY (2010) Residual cancer stem cells after interval cytoreductive surgery following neoadjuvant chemotherapy could result in poor treatment outcomes for ovarian cancer. Onkologie 33:324–330. https://doi.org/10.1159/ 000313823

- Shah MM, Landen CN (2014) Ovarian cancer stem cells: Are they real and why are they important? Gynecol Oncol 132:483–489. https://doi.org/10. 1016/j.ygyno.2013.12.001
- Lupia M, Cavallaro U (2017) Ovarian cancer stem cells: Still an elusive entity? Mol Cancer 16:64. https://doi.org/10.1186/s12943-017-0638-3
- Ayob AZ, Ramasamy TS (2018) Cancer stem cells as key drivers of tumour progression. J Biomed Sci 25:20. https://doi.org/10.1186/s12929-018-0426-4
- 43. Beets-Tan RGH, Beets GL (2014) MRI for assessing and predicting response to neoadjuvant treatment in rectal cancer. Nat Rev Gastro Hepat 11: 480–488. https://doi.org/10.1038/nrgastro.2014.41

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.